期刊
ACTA PHARMACEUTICA SINICA B
卷 6, 期 1, 页码 32-45出版社
INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2015.11.004
关键词
5-Lipoxygenase; 5-LOX inhibitors; Pyrazole derivatives; Leukotrienes-related diseases; In vivo; Benzo-fuse heterocyle; Ischemic incults; Brain inflammation
资金
- National Natural Science Foundation of China [91229204, 81220108025]
- Major Project of Chinese National Programs for Fundamental Research and Development [2015CB910304]
- National High Technology Research and Development Program of China [2012AA020302]
- National Basic Research Program of China [2012CB518005]
- National S&T Major Projects [2012ZX09103101-072, 2014ZX09507002-001, 2013ZX09507-001]
Human 5-lipoxygenase (5-LOX) is a well-validated drug target and its inhibitors are potential drugs for treating leukotriene-related disorders. Our previous work on structural optimization of the hit compound 2 from our in-house collection identified two lead compounds, 3a and 3b, exhibiting a potent inhibitory profile against 5-LOX with IC50 values less than 1 mu mol/L in cell-based assays. Here, we further optimized these compounds to prepare a class of novel pyrazole derivatives by opening the fused ring system. Several new compounds exhibited more potent inhibitory activity than the lead compounds against 5-LOX. In particular, compound 4e not only suppressed lipopolysaccharide-induced inflammation in brain inflammatory cells and protected neurons from oxidative toxicity, but also significantly decreased infarct damage in a mouse model of cerebral ischemia. Molecular docking analysis further confirmed the consistency of our theoretical results and experimental data. In conclusion, the excellent in vitro and in vivo inhibitory activities of these compounds against 5-LOX suggested that these novel chemical structures have a promising therapeutic potential to treat leukotriene-related disorders. (C) 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据